Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Circ Heart Fail. 2018 Feb;11(2):e004000. doi: 10.1161/CIRCHEARTFAILURE.117.004000

Table 3.

Values of variables associated with survival at 1-year follow-up evaluations in untreated vs. diflunisal-treated ATTRwt patients

Variable, median (range) Untreated (n = 23) Diflunisal-treated (n = 12) P
TTR (mg/dL) 22 (12 – 29) 30 (25 – 43) < 0.001
cTn-I (ng/mL) 0.096 (0.021 – 0.376) 0.058 (0.006 – 0.328) 0.008

ATTRwt indicates wild-type transthyretin amyloidosis; TTR, transthyretin; and, cTn-I, cardiac troponin I

HHS Vulnerability Disclosure